S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Biden and GOP rush to finalize debt ceiling deal, shore up support to prevent default
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
66,000% upside on tiny biotech? (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
66,000% upside on tiny biotech? (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Biden and GOP rush to finalize debt ceiling deal, shore up support to prevent default
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
66,000% upside on tiny biotech? (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
66,000% upside on tiny biotech? (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Biden and GOP rush to finalize debt ceiling deal, shore up support to prevent default
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
66,000% upside on tiny biotech? (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
66,000% upside on tiny biotech? (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Biden and GOP rush to finalize debt ceiling deal, shore up support to prevent default
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
66,000% upside on tiny biotech? (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
66,000% upside on tiny biotech? (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
NASDAQ:ALNY

Alnylam Pharmaceuticals (ALNY) Stock Forecast, Price & News

$188.26
+2.26 (+1.22%)
(As of 05/26/2023 ET)
Compare
Today's Range
$184.06
$188.87
50-Day Range
$185.92
$212.05
52-Week Range
$120.43
$242.97
Volume
426,725 shs
Average Volume
599,164 shs
Market Capitalization
$23.44 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$247.20

Alnylam Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
31.3% Upside
$247.20 Price Target
Short Interest
Bearish
4.11% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.52
Upright™ Environmental Score
News Sentiment
0.74mentions of Alnylam Pharmaceuticals in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$7.13 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($6.46) to ($3.17) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.46 out of 5 stars

Medical Sector

175th out of 1,012 stocks

Pharmaceutical Preparations Industry

69th out of 495 stocks


ALNY stock logo

About Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals, Inc. is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. Its products include ONPATTRO, GIVLAARI, and OXLUMO. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Receive ALNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ALNY Stock News Headlines

NOTICE: Your retirement is in immediate danger
Soon you may be forced to spend your afternoons packing grocery bags at Walmart instead of going to the park with your grandchildren. Why? Because not only could your money be worth even less than it already is now, but certain stocks and cryptocurrencies could drop by 80%. Even your social security check could be worth 21% less! Learn how to protect your retirement here >>>
Bank Collapse Causes Gold Prices to Soar
Silicon Valley Bank was the second-largest bank in American history to fail, and investors have started piling into the safety and security of gold. But if you're not taking advantage of a little-known way to invest for around $5 today, you're missing out.
Alnylam Pharmaceuticals (NASDAQ:ALNY) Trading Down 5.3%
H.C. Wainwright Remains a Buy on Alnylam Pharma (ALNY)
Alnylam Pharma (ALNY) Receives a Buy from BMO Capital
Needham Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)
Berenberg Bank Keeps Their Hold Rating on Alnylam Pharma (ALNY)
See More Headlines
Receive ALNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ALNY Company Calendar

Last Earnings
5/04/2023
Today
5/28/2023
Next Earnings (Estimated)
7/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:ALNY
CUSIP
02043Q10
Employees
2,002
Year Founded
2002

Price Target and Rating

Average Stock Price Forecast
$247.20
High Stock Price Forecast
$415.00
Low Stock Price Forecast
$143.00
Forecasted Upside/Downside
+31.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
21 Analysts

Profitability

Net Income
$-1,131,160,000.00
Pretax Margin
-92.70%

Debt

Sales & Book Value

Annual Sales
$1.04 billion
Book Value
($2.08) per share

Miscellaneous

Free Float
122,783,000
Market Cap
$23.44 billion
Optionable
Optionable
Beta
0.48

Social Links


Key Executives

  • Yvonne L. GreenstreetYvonne L. Greenstreet
    Chief Executive Officer & Director
  • Akshay K. VaishnawAkshay K. Vaishnaw
    President
  • Jeffrey V. Poulton
    Chief Financial Officer & Executive Vice President
  • Pushkal P. Garg
    Chief Medical Officer & EVP-Medical Affairs
  • James P. Bilotta
    Chief Information Officer & SVP













ALNY Stock - Frequently Asked Questions

Should I buy or sell Alnylam Pharmaceuticals stock right now?

21 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There are currently 6 hold ratings and 15 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ALNY shares.
View ALNY analyst ratings
or view top-rated stocks.

What is Alnylam Pharmaceuticals' stock price forecast for 2023?

21 brokerages have issued twelve-month target prices for Alnylam Pharmaceuticals' stock. Their ALNY share price forecasts range from $143.00 to $415.00. On average, they predict the company's stock price to reach $247.20 in the next year. This suggests a possible upside of 31.3% from the stock's current price.
View analysts price targets for ALNY
or view top-rated stocks among Wall Street analysts.

How have ALNY shares performed in 2023?

Alnylam Pharmaceuticals' stock was trading at $237.65 on January 1st, 2023. Since then, ALNY shares have decreased by 20.8% and is now trading at $188.26.
View the best growth stocks for 2023 here
.

When is Alnylam Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 27th 2023.
View our ALNY earnings forecast
.

How were Alnylam Pharmaceuticals' earnings last quarter?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) released its earnings results on Thursday, May, 4th. The biopharmaceutical company reported ($1.40) earnings per share for the quarter, beating analysts' consensus estimates of ($1.97) by $0.57. The biopharmaceutical company had revenue of $319.29 million for the quarter, compared to analyst estimates of $312.53 million. Alnylam Pharmaceuticals had a negative trailing twelve-month return on equity of 1,287.80% and a negative net margin of 93.13%. Alnylam Pharmaceuticals's revenue was up 49.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($2.00) earnings per share.

What guidance has Alnylam Pharmaceuticals issued on next quarter's earnings?

Alnylam Pharmaceuticals updated its FY 2023 earnings guidance on Thursday, May, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.30 billion-$1.46 billion, compared to the consensus revenue estimate of $1.39 billion.

What is John M. Maraganore's approval rating as Alnylam Pharmaceuticals' CEO?

65 employees have rated Alnylam Pharmaceuticals Chief Executive Officer John M. Maraganore on Glassdoor.com. John M. Maraganore has an approval rating of 99% among the company's employees. This puts John M. Maraganore in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Alnylam Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), NVIDIA (NVDA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), AbbVie (ABBV), Micron Technology (MU) and Advanced Micro Devices (AMD).

What is Alnylam Pharmaceuticals' stock symbol?

Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."

Who are Alnylam Pharmaceuticals' major shareholders?

Alnylam Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (10.58%), Baillie Gifford & Co. (6.97%), BlackRock Inc. (6.87%), Wellington Management Group LLP (4.94%), Price T Rowe Associates Inc. MD (3.19%) and Dodge & Cox (3.13%). Insiders that own company stock include Akshay Vaishnaw, Barry E Greene, Indrani Lall Franchini, Jeffrey V Poulton, Jeffrey W Dunn, John Maraganore, Laurie Keating, Phillip A Sharp, Pushkal Garg, Steven M Paul, Tolga Tanguler and Yvonne Greenstreet.
View institutional ownership trends
.

How do I buy shares of Alnylam Pharmaceuticals?

Shares of ALNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alnylam Pharmaceuticals' stock price today?

One share of ALNY stock can currently be purchased for approximately $188.26.

How much money does Alnylam Pharmaceuticals make?

Alnylam Pharmaceuticals (NASDAQ:ALNY) has a market capitalization of $23.44 billion and generates $1.04 billion in revenue each year. The biopharmaceutical company earns $-1,131,160,000.00 in net income (profit) each year or ($8.69) on an earnings per share basis.

How many employees does Alnylam Pharmaceuticals have?

The company employs 2,002 workers across the globe.

How can I contact Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals' mailing address is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. The official website for the company is www.alnylam.com. The biopharmaceutical company can be reached via phone at (617) 551-8200, via email at investors@alnylam.com, or via fax at 617-551-8101.

This page (NASDAQ:ALNY) was last updated on 5/28/2023 by MarketBeat.com Staff

My Account -